​

BridgeBio Oncology Therapeutics (BBOT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BBOT Stock Forecast

BridgeBio Oncology Therapeutics (BBOT) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $22.00 and a low of $15.00. This represents a 363.41% increase from the last price of $4.10.

BBOT Stock Rating

BridgeBio Oncology Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

BBOT Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Oncology Therapeutics363.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts338
Avg Price Target$19.00$19.00$20.63
Last Closing Price$4.10$4.10$4.10
Upside/Downside363.41%363.41%403.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2647---11
Aug, 2647---11
Jul, 2637---10
Jun, 2637---10
May, 2636---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Sean McCutcheonRaymond James$22.00$8.52158.22%436.59%
Sep 09, 2026Stifel Nicolaus$15.00$8.8669.30%265.85%
Sep 09, 2026Canaccord Genuity$20.00$8.86125.73%387.80%
May 11, 2026John NewmanCanaccord Genuity$23.00$7.66200.26%460.98%
Feb 10, 2026Laura PrendergastStifel Nicolaus$23.00$10.84112.18%460.98%
Jan 09, 2026Raymond James$24.00$13.3080.45%485.37%
Jan 08, 2026Morgan Stanley$18.00$12.9239.32%339.02%
Dec 05, 2025Morgan Stanley$20.00$11.5473.31%387.80%
Sep 17, 2025Leerink Partners$25.00$10.79131.70%509.76%
Sep 15, 2025Robert BurnsH.C. Wainwright$27.00$9.73177.49%558.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2026Raymond JamesOutperformOutperformhold
Jul 08, 2026UBSOverweightdowngrade
Jan 09, 2026Raymond JamesOutperforminitialise
Dec 05, 2025Morgan StanleyOverweightinitialise
Sep 15, 2025H.C. WainwrightBuyinitialise
Sep 04, 2025OppenheimerOutperforminitialise
Aug 15, 2025Piper SandlerOverweightinitialise
Aug 13, 2025Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-300 $-230 $-160 $-90 $-20 $50 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$0.46$-4.30--
Avg Forecast$-268.56$-2.28$-2.11$-2.46
High Forecast$-268.56$-1.38$-1.36$-2.46
Low Forecast$-268.56$-3.45$-3.52$-2.46
Surprise %-100.17%88.60%--

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

Net Income Forecast

$-5B $-4B $-3B $-2B $-900M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-74.28M$-134.04M--
Avg Forecast$-4.47B$-40.18M$-40.59M$-40.92M
High Forecast$-4.47B$-22.96M$-22.62M$-40.92M
Low Forecast$-4.47B$-57.39M$-58.56M$-40.92M
Surprise %-98.34%233.64%--

BBOT Forecast FAQ

Is BridgeBio Oncology Therapeutics stock a buy?

BridgeBio Oncology Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Oncology Therapeutics is a favorable investment for most analysts.

What is BridgeBio Oncology Therapeutics's price target?

BridgeBio Oncology Therapeutics's price target, set by 8 Wall Street analysts, averages $19 over the next 12 months. The price target range spans from $15 at the low end to $22 at the high end, suggesting a potential 363.41% change from the previous closing price of $4.1.

How does BridgeBio Oncology Therapeutics stock forecast compare to its benchmarks?

BridgeBio Oncology Therapeutics's stock forecast shows a 363.41% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BridgeBio Oncology Therapeutics over the past three months?

  • September 2026: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Oncology Therapeutics’s EPS forecast?

BridgeBio Oncology Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.11, marking a -50.93% decrease from the reported $-4.3 in 2025. Estimates for the following years are.

What is BridgeBio Oncology Therapeutics’s revenue forecast?

BridgeBio Oncology Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is BridgeBio Oncology Therapeutics’s net income forecast?

BridgeBio Oncology Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-40.592M, representing a -69.72% decrease from the reported $-134M in 2025. Projections indicate .